Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Jahr

2023

Autoren

Coles AJ, Achiron A, Traboulsee A, Singer BA, Pozzilli C, Oreja-Guevara C, Giovannoni G, Comi G, Freedman MS, Ziemssen T, Shiota D, Rawlings AM, Wong AT, Chirieac M, Montalban X.

Verlag

Ther Adv Neurol Disord. 2023 Sep 21;16:17562864231194823.

Link

https://doi.org/10.1177/17562864231194823

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Ziemssen T, Centonze D. Diagnostic uncertainty in the era of biosimilar natalizumab-The case for harmonizing anti-JCV antibody testing. Mult Scler. 2025 Jun;31(7):751-753. doi: 10.1177/13524585251346658. Epub 2025 Jun 14. PMID: 40515640.

Speech as a digital biomarker in multiple sclerosis: Automatic analysis of speech metrics using a multi-speech-task protocol in a cross-sectional MS cohort study

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany

RECLAIM—A retrospective, multicenter observational study aimed at enabling the development of artificial intelligence-driven prognostic models for disease progression in multiple sclerosis

Experiences of People with Multiple Sclerosis in Sensor-Based Jump Assessment